ARTICLE | Company News
Amrad, Merck deal
November 24, 2003 8:00 AM UTC
AML received a $3 million milestone from MRK subsidiary Merck Sharp & Dohme Pty. Ltd. (Sydney, Australia) as part of their June deal to develop compounds based on AML's cytokine IL-13 receptor alpha t...